Idiopathic pulmonary fibrosis (IPF)

J. Behr (Munich, Germany)

Source: ERS Course 2016

Number: 5

Disease area: Interstitial lung diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Behr (Munich, Germany). Idiopathic pulmonary fibrosis (IPF). ERS Course 2016

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013
Idiopathic pulmonary fibrosis Source: Eur Respir Monogr 2015; 68: 50-63 Year: 2015
Idiopathic pulmonary fibrosis Source: International Congress 2018 – State of the art session: Interstitial lung diseases Year: 2018
Idiopathic pulmonary fibrosis Source: Eur Respir Monogr 2013; 62: 37-53 Year: 2013
Idiopathic pulmonary fibrosis Source: School Course 2014 - Interstitial lung diseases Year: 2014
Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2006 - Clinical physiology Year: 2006
Idiopathic pulmonary fibrosis (IPF): the patient journey Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020
Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease Year: 2011
Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom? Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment Year: 2006
Idiopathic pulmonary fibrosis - IPF Source: Respipedia Article Year: 2018
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013
Towards a better diagnosis of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - Idiopathic pulmonary fibrosis: present understandings and future directions Year: 2010
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016
Idiopathic pulmonary fibrosis and pirfenidone Source: Eur Respir J 2010; 35: 728-729 Year: 2010
Idiopathic pulmonary upper lobe fibrosis shows distinct features and poor prognosis compared to idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013
Handigrip strenght and dynapenia in patients with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020
The circulating metabolome in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019
Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013
Changes in the small airways in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013